|Articles|October 28, 1998
Epix lands drug-discovery partner
Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry
Advertisement
Epix Medical of Cambridge, MA, has signed an agreement with drug discovery firm NeoGenesis Pharmaceuticals, also of Cambridge, that may lead to quick development of new contrast agents. Under the deal, Epix will gain access to combinatorial chemistry laboratories owned by NeoGenesis that enable the rapid screening of compounds that could be used to form new products. Epix hopes the deal will enable it to find new advanced MRI contrast agents.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Diagnostic Imaging’s Weekly Scan: August 16 — August 22
2
From Complexity to Confidence: Reducing Cognitive Load in Modern CT Imaging
3
Could Photon Counting CT Enhance Local Staging of Bladder Cancer?
4
Interventional Radiology in Focus: Emphasizing the Appeal, Advances and Awareness for Interventional Radiology
5









